Blog
XEVMPD and Internet Explorer
Internet Explorer is coming to end of its lifetime on 15th of June 2022 and EMA has given us almost no instructions how to proceed with usage of XEVMPD. Not to worry, read below to see what you should do if you face problems in June.
EMA report echoes our calls on MAHs to stop signal detection activities in EudraVigilance
An analysis of the EMA’s pilot program report which the European Commision received from the European Medicines Agency (EMA) after 18 months of the pilot in the fall of 2019.
The latest “updates” on UK PV from MHRA after Brexit
Some of the Brexit related updates and transition were completed by the end of 2020 and last parts became finally effective in the beginning of 2022. But legislators and MHRA still have plenty of work to do to provide clarity for license holders in the UK.
Why is France reporting so many deaths caused by adverse drug reactions?
According to the Eurostat data, on average more than half of all deaths caused by an adverse drug reaction in Europe happen in France. Why?
Let’s have a chat
Whatever you needs are, we look forward to getting in touch with you.
Feel free to drop us a message and we will contact you right away.
Tepsivo Oy | Haartmaninkatu 4, Building 14, 00290, Helsinki, Finland | VAT number FI31367614 | contact@tepsivo.com | +358 402 204 698 | Privacy policy



